<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39323767</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2976-8713</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>RSC pharmaceutics</Title><ISOAbbreviation>RSC Pharm</ISOAbbreviation></Journal><ArticleTitle>Tailoring lipid nanoparticle dimensions through manufacturing processes.</ArticleTitle><Pagination><StartPage>841</StartPage><EndPage>853</EndPage><MedlinePgn>841-853</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d4pm00128a</ELocationID><Abstract><AbstractText>Lipid nanoparticles (LNPs), most commonly recognised for their role in COVID-19 mRNA vaccines, are important delivery vehicles for nucleic acid (mRNA, siRNA) therapies. The physicochemical attributes, such as size, nucleic acid encapsulation and electric charge, may have a significant impact on the efficacy of these medicines. In this study, adjustments to aqueous to lipid phase ratios were assessed for their impact on LNP size and other critical quality attributes (CQAs). It was observed that minor adjustments of aqueous-to-organic lipid phase ratios can be used to precisely control the size of ALC-0315-formulated LNPs. This was then used to evaluate the impact of phase ratio and corresponding size ranges on the <i>in vitro</i> and <i>in vivo</i> expression of these LNPs. In HEK293 cells, larger LNPs led to higher expression of the mRNA cargo within the LNPs, with a linear correlation between size and expression. In THP-1 cells this preference for larger LNPs was observed up to 120 d.nm after which there was a fall in expression. In BALB/c mice, however, LNPs at the lowest phase ratio tested, &gt;120 d.nm, showed reduced expression compared to those of range 60-120 d.nm, within which there was no significant difference between sizes. These results suggest a robustness of LNP expression up to 120 d.nm, larger than those &lt;100 d.nm conventionally used in medicine.</AbstractText><CopyrightInformation>This journal is © The Royal Society of Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McMillan</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0006-7335-3888</Identifier><AffiliationInfo><Affiliation>University of Strathclyde Glasgow UK yvonne.perrie@strath.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Druschitz</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Croda International Plc and Avanti Polar Lipids Alabaster AL USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rumbelow</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Croda International Plc and Avanti Polar Lipids Alabaster AL USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borah</LastName><ForeName>Ankita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Strathclyde Glasgow UK yvonne.perrie@strath.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binici</LastName><ForeName>Burcu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University of Strathclyde Glasgow UK yvonne.perrie@strath.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rattray</LastName><ForeName>Zahra</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-8371-8549</Identifier><AffiliationInfo><Affiliation>University of Strathclyde Glasgow UK yvonne.perrie@strath.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrie</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>University of Strathclyde Glasgow UK yvonne.perrie@strath.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RSC Pharm</MedlineTA><NlmUniqueID>9918803387106676</NlmUniqueID></MedlineJournalInfo><CoiStatement>There are no conflicts to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>4</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39323767</ArticleId><ArticleId IdType="pmc">PMC11417672</ArticleId><ArticleId IdType="doi">10.1039/d4pm00128a</ArticleId><ArticleId IdType="pii">d4pm00128a</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiaie S. H. Majidi Zolbanin N. Ahmadi A. Bagherifar R. Valizadeh H. Kashanchi F. et al., Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. J. Nanobiotechnol. 2022;20(1):276. doi: 10.1186/s12951-022-01478-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-022-01478-7</ArticleId><ArticleId IdType="pmc">PMC9194786</ArticleId><ArticleId IdType="pubmed">35701851</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C. Ma Y. Zhang J. Kuo J. C. Zhang Z. Xie H. et al., Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy. Molecules. 2022;27(6):1943. doi: 10.3390/molecules27061943.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27061943</ArticleId><ArticleId IdType="pmc">PMC8949521</ArticleId><ArticleId IdType="pubmed">35335310</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassett K. J. Higgins J. Woods A. Levy B. Xia Y. Hsiao C. J. et al., Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J. Controlled Release. 2021;335:237–246. doi: 10.1016/j.jconrel.2021.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2021.05.021</ArticleId><ArticleId IdType="pubmed">34019945</ArticleId></ArticleIdList></Reference><Reference><Citation>
NCBI, Lipid+nanoparticle – search results – PubMed: United States National Library of Medicine, 2023 available from: https://pubmed.ncbi.nlm.nih.gov/?term=lipid%2Bnanoparticle</Citation></Reference><Reference><Citation>Hou X. Zaks T. Langer R. Dong Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 2021;6(12):1078–1094. doi: 10.1038/s41578-021-00358-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41578-021-00358-0</ArticleId><ArticleId IdType="pmc">PMC8353930</ArticleId><ArticleId IdType="pubmed">34394960</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd S. J. Han X. Mukalel A. J. El-Mayta R. Thatte A. S. Wu J. et al., Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines. Proc. Natl. Acad. Sci. U. S. A. 2023;120(33):e2303567120. doi: 10.1073/pnas.2303567120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2303567120</ArticleId><ArticleId IdType="pmc">PMC10438381</ArticleId><ArticleId IdType="pubmed">37556502</ArticleId></ArticleIdList></Reference><Reference><Citation>Roces C. B. Port E. C. Daskalakis N. N. Watts J. A. Aylott J. W. Halbert G. W. et al., Rapid scale-up and production of active-loaded PEGylated liposomes. Int. J. Pharm. 2020;586:119566. doi: 10.1016/j.ijpharm.2020.119566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2020.119566</ArticleId><ArticleId IdType="pubmed">32622812</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S. Dhawan V. Holm R. Nagarsenker M. S. Perrie Y. Liposomes: Advancements and innovation in the manufacturing process. Adv. Drug Delivery Rev. 2020;154–155:102–122. doi: 10.1016/j.addr.2020.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2020.07.002</ArticleId><ArticleId IdType="pubmed">32650041</ArticleId></ArticleIdList></Reference><Reference><Citation>Di J. Du Z. Wu K. Jin S. Wang X. Li T. et al., Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size. Pharm. Res. 2022;39(1):105–114. doi: 10.1007/s11095-022-03166-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-022-03166-5</ArticleId><ArticleId IdType="pmc">PMC8791091</ArticleId><ArticleId IdType="pubmed">35080707</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter M. R. Cui L. Porebski B. T. Pereira S. Sonzini S. Odunze U. et al., Understanding Intracellular Biology to Improve mRNA Delivery by Lipid Nanoparticles. Small Methods. 2023:e2201695. doi: 10.1002/smtd.202201695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smtd.202201695</ArticleId><ArticleId IdType="pmc">PMC7615154</ArticleId><ArticleId IdType="pubmed">37317010</ArticleId></ArticleIdList></Reference><Reference><Citation>Roces C. B. Lou G. Jain N. Abraham S. Thomas A. Halbert G. W. et al., Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics. Pharmaceutics. 2020;12(11):1095. doi: 10.3390/pharmaceutics12111095.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12111095</ArticleId><ArticleId IdType="pmc">PMC7697682</ArticleId><ArticleId IdType="pubmed">33203082</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou G. Anderluzzi G. Woods S. Roberts C. W. Perrie Y. A novel microfluidic-based approach to formulate size-tuneable large unilamellar cationic liposomes: Formulation, cellular uptake and biodistribution investigations. Eur. J. Pharm. Biopharm. 2019;143:51–60. doi: 10.1016/j.ejpb.2019.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2019.08.013</ArticleId><ArticleId IdType="pubmed">31445156</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka H. Takata N. Sakurai Y. Yoshida T. Inoue T. Tamagawa S. et al., Delivery of Oligonucleotides Using a Self-Degradable Lipid-Like Material. Pharmaceutics. 2021;13(4):544. doi: 10.3390/pharmaceutics13040544.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13040544</ArticleId><ArticleId IdType="pmc">PMC8070490</ArticleId><ArticleId IdType="pubmed">33924589</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeki M. Fujishima Y. Sato Y. Yasui T. Kaji N. Ishida A. et al., Understanding the formation mechanism of lipid nanoparticles in microfluidic devices with chaotic micromixers. PLoS One. 2017;12(11):e0187962. doi: 10.1371/journal.pone.0187962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0187962</ArticleId><ArticleId IdType="pmc">PMC5705116</ArticleId><ArticleId IdType="pubmed">29182626</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipe V. Hawe A. Jiskoot W. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm. Res. 2010;27(5):796–810. doi: 10.1007/s11095-010-0073-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-010-0073-2</ArticleId><ArticleId IdType="pmc">PMC2852530</ArticleId><ArticleId IdType="pubmed">20204471</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim A. Ng W. B. Bernt W. Cho N. J. Validation of Size Estimation of Nanoparticle Tracking Analysis on Polydisperse Macromolecule Assembly. Sci. Rep. 2019;9(1):2639. doi: 10.1038/s41598-019-38915-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-38915-x</ArticleId><ArticleId IdType="pmc">PMC6389903</ArticleId><ArticleId IdType="pubmed">30804441</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhigaltsev I. V. Belliveau N. Hafez I. Leung A. K. Huft J. Hansen C. et al., Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. Langmuir. 2012;28(7):3633–3640. doi: 10.1021/la204833h.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/la204833h</ArticleId><ArticleId IdType="pubmed">22268499</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki Y. Ishihara H. Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs. Drug Metab. Pharmacokinet. 2021;41:100424. doi: 10.1016/j.dmpk.2021.100424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dmpk.2021.100424</ArticleId><ArticleId IdType="pmc">PMC8502116</ArticleId><ArticleId IdType="pubmed">34757287</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P. Ibrahim N. M. Cheng K. The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA. Trends Pharmacol. Sci. 2021;42(6):448–460. doi: 10.1016/j.tips.2021.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2021.03.002</ArticleId><ArticleId IdType="pmc">PMC8148296</ArticleId><ArticleId IdType="pubmed">33875229</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenchov R. Bird R. Curtze A. E. Zhou Q. Lipid Nanoparticles—From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano. 2021;15(11):16982–17015. doi: 10.1021/acsnano.1c04996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.1c04996</ArticleId><ArticleId IdType="pubmed">34181394</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni J. A. Darjuan M. M. Mercer J. E. Chen S. van der Meel R. Thewalt J. L. et al., On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA. ACS Nano. 2018;12(5):4787–4795. doi: 10.1021/acsnano.8b01516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.8b01516</ArticleId><ArticleId IdType="pubmed">29614232</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng M. H. Y. Leung J. Zhang Y. Strong C. Basha G. Momeni A. et al., Induction of Bleb Structures in Lipid Nanoparticle Formulations of mRNA Leads to Improved Transfection Potency. Adv. Mater. 2023;35(31):e2303370. doi: 10.1002/adma.202303370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.202303370</ArticleId><ArticleId IdType="pubmed">37172950</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb C. Khadke S. Schmidt S. T. Roces C. B. Forbes N. Berrie G. et al., The Impact of Solvent Selection: Strategies to Guide the Manufacturing of Liposomes Using Microfluidics. Pharmaceutics. 2019;11(12):653. doi: 10.3390/pharmaceutics11120653.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics11120653</ArticleId><ArticleId IdType="pmc">PMC6955969</ArticleId><ArticleId IdType="pubmed">31817217</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciolino N. Reverdatto S. Premo A. Breindel L. Yu J. Theophall G. et al., Messenger RNA in lipid nanoparticles rescues HEK 293 cells from lipid-induced mitochondrial dysfunction as studied by real time pulse chase NMR, RTPC-NMR, spectroscopy. Sci. Rep. 2022;12(1):22293. doi: 10.1038/s41598-022-26444-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-26444-z</ArticleId><ArticleId IdType="pmc">PMC9789524</ArticleId><ArticleId IdType="pubmed">36566335</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui L. Renzi S. Quagliarini E. Digiacomo L. Amenitsch H. Masuelli L. et al., Efficient Delivery of DNA Using Lipid Nanoparticles. Pharmaceutics. 2022;14(8):1698. doi: 10.3390/pharmaceutics14081698.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14081698</ArticleId><ArticleId IdType="pmc">PMC9416266</ArticleId><ArticleId IdType="pubmed">36015328</ArticleId></ArticleIdList></Reference><Reference><Citation>Long J. Yu C. Zhang H. Cao Y. Sang Y. Lu H. et al., Novel Ionizable Lipid Nanoparticles for SARS–CoV–2 Omicron mRNA Delivery. Adv. Healthcare Mater. 2023;12(13):2202590. doi: 10.1002/adhm.202202590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adhm.202202590</ArticleId><ArticleId IdType="pmc">PMC11468017</ArticleId><ArticleId IdType="pubmed">36716702</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng X. Lee R. J. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv. Drug Delivery Rev. 2016;99(Pt A):129–137. doi: 10.1016/j.addr.2016.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2016.01.022</ArticleId><ArticleId IdType="pubmed">26900977</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer R. A. Neshat S. Y. Green J. J. Santos J. L. Tuesca A. D. Targeting strategies for mRNA delivery. Mater. Today Adv. 2022;14(2):100240. doi: 10.1016/j.mtadv.2022.100240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mtadv.2022.100240</ArticleId></ArticleIdList></Reference><Reference><Citation>Paunovska K. Sago C. D. Monaco C. M. Hudson W. H. Castro M. G. Rudoltz T. G. et al., A Direct Comparison of in Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of Nanoparticles Reveals a Weak Correlation. Nano Lett. 2018;18(3):2148–2157. doi: 10.1021/acs.nanolett.8b00432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.nanolett.8b00432</ArticleId><ArticleId IdType="pmc">PMC6054134</ArticleId><ArticleId IdType="pubmed">29489381</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain P. Pawar R. S. Pandey R. S. Madan J. Pawar S. Lakshmi P. K. et al., In vitro in vivo correlation (IVIVC) in nanomedicine: Is protein corona the missing link? Biotechnol. Adv. 2017;35(7):889–904. doi: 10.1016/j.biotechadv.2017.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biotechadv.2017.08.003</ArticleId><ArticleId IdType="pubmed">28844973</ArticleId></ArticleIdList></Reference><Reference><Citation>Francia V. Schiffelers R. M. Cullis P. R. Witzigmann D. The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy. Bioconjugate Chem. 2020;31(9):2046–2059. doi: 10.1021/acs.bioconjchem.0c00366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.bioconjchem.0c00366</ArticleId><ArticleId IdType="pubmed">32786370</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y. Jeong M. Park J. Jung H. Lee H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp. Mol. Med. 2023;55(10):2085–2096. doi: 10.1038/s12276-023-01086-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-023-01086-x</ArticleId><ArticleId IdType="pmc">PMC10618257</ArticleId><ArticleId IdType="pubmed">37779140</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L. More K. R. Ojha A. Jackson C. B. Quinlan B. D. Li H. et al., Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. npj Vaccines. 2023;8(1):156. doi: 10.1038/s41541-023-00751-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00751-6</ArticleId><ArticleId IdType="pmc">PMC10567765</ArticleId><ArticleId IdType="pubmed">37821446</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>